LTV:CAC RatioHealthTechSeries B

LTV:CAC Ratio for HealthTech at Series B

2026 data · Sample size: 514 · Source: Bain NPS & Customer Loyalty Insights

25th %ile

2.46x

Median

3.63x

75th %ile

5.58x

90th %ile

6.95x

▬Trending stable year-over-year

About This Metric

Ratio of customer lifetime value to acquisition cost. 3:1 or higher indicates healthy unit economics.

LTV / CAC

Higher is better · Unit: ratio

How to Improve

Focus on reducing CAC by optimizing inbound channels while simultaneously expanding LTV through upsell motions. Shift spending from low‑converting paid channels to organic and community‑driven acquisition. Implement a product‑qualified lead model that lets prospects self‑qualify before sales engagement. Build usage‑based pricing to naturally increase revenue as customers grow. Invest in retention to extend average customer lifetime.

Ehsan's Analysis

HealthTech LTV:CAC ratios look spectacular on paper — 8-15x is common — because LTV is enormous (multi-year contracts with near-zero churn) and CAC, while high, is amortized over a very long customer lifetime. But this ratio is misleading because it ignores time value. A 10x LTV:CAC with 36-month payback and 5-year customer lifetime is mathematically equivalent to a 3x ratio with 6-month payback in present-value terms. Healthtech founders use their impressive LTV:CAC to justify current burn rates, but investors are increasingly discounting the ratio by the payback period. The metric that healthtech boards should track: "capital efficiency ratio" = total ARR generated / total capital raised. Median healthtech capital efficiency is 0.3-0.5x (you raise $10M to generate $3-5M ARR), versus 0.8-1.2x for SaaS. This is the real measure of whether your unit economics work, not the impressive-but-misleading headline LTV:CAC.

Ehsan Jahandarpour

AI Growth Strategist & Fractional CMO

Forbes Top 20 Growth Hacker · TEDx Speaker · 716 Academic Citations · Ex-Microsoft · CMO at FirstWave (ASX:FCT) · Forbes Communications Council

Frequently Asked Questions

What is a good LTV:CAC Ratio for HealthTech companies at Series B stage?

The median LTV:CAC Ratio for HealthTech companies at the Series B stage is 3.63. Top‑quartile companies (75th percentile) significantly outperform this baseline. The most important factor is consistent improvement over time rather than hitting any single target number.

How does LTV:CAC Ratio differ by company stage in HealthTech?

LTV:CAC Ratio typically improves as HealthTech companies mature from seed through growth stage. Earlier‑stage companies should benchmark against stage‑appropriate peers rather than comparing themselves to mature companies.

How often should HealthTech companies measure LTV:CAC Ratio?

HealthTech companies at the Series B stage should track LTV:CAC Ratio monthly with quarterly deep‑dive analysis. Set up automated dashboards and alerts for significant deviations from your baseline.

What factors most impact LTV:CAC Ratio in the HealthTech sector?

In HealthTech, the primary factors impacting LTV:CAC Ratio include product‑market fit maturity, competitive landscape intensity, customer segmentation strategy, pricing optimization, and operational efficiency. Series B‑stage companies should focus on the one or two highest‑leverage factors rather than trying to optimize everything simultaneously.

How does LTV:CAC Ratio for HealthTech compare to cross‑industry benchmarks?

HealthTech LTV:CAC Ratio benchmarks can differ significantly from cross‑industry averages due to factors specific to the HealthTech vertical including customer acquisition dynamics, competitive intensity, and typical deal sizes. Always compare against industry‑specific benchmarks rather than broad averages for meaningful insights.